OR WAIT null SECS
- About Us
- Advertise
- Editorial
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2022 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
EQT makes $2.1B bid to purchase Recipharm
As it awaits status of Moderna vaccine, Swedish CDMO receives tender
Private equity firm EQT AB has made an offer to acquire Recipharm AB, a contract development and manufacturing organization (CDMO), for $2.1 billion, EQT announced. The offer is expected to be made public on or around Dec. 17.
As Bloomberg reported, Sweden-based EQT has already secured ownership of about 25.7% of the shares and 74.3% of the votes in Recipharm via its chairman, Lars Backsell, and Thomas Eldered, its CEO.
The firm will be offering shareholders $26.24 in cash per share, the report stated.
Other reports noted that Recipharm recently signed a preliminary deal with Moderna Inc to fill and seal the packaging for the biotech's mRNA Covid-19 vaccine.
Recipharm signed a letter of intent with Moderna to help "formulate, fill and finish" its Covid-19 vaccine, as an FDA advisory board prepares to meet on Thursday to discuss Moderna's request for emergency use authorization (EUA).